https://www.selleckchem.com/pr....oducts/dlin-kc2-dma.
thresholds having delayed or inappropriate treatment. The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be used to sensitize cancer cells to such drugs. We tested recently synthesized new generation inhibitors of this interaction and evaluated their capacity to sensitize cancer c
Like
Comment
Share
